HBM Holdings (HKSE:02142) Inventories, Raw Materials & Components : HK$0.0 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is HBM Holdings Inventories, Raw Materials & Components?

HBM Holdings's inventories, raw materials & components for the quarter that ended in Jun. 2024 was HK$0.0 Mil.

HBM Holdings's annual raw materials increased from Dec. 2021 (HK$0.0 Mil) to Dec. 2022 (HK$8.1 Mil) but then declined from Dec. 2022 (HK$8.1 Mil) to Dec. 2023 (HK$0.0 Mil).

HBM Holdings Inventories, Raw Materials & Components Historical Data

The historical data trend for HBM Holdings's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Inventories, Raw Materials & Components Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Raw Materials & Components

Get a 7-Day Free Trial

8.13

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Inventories, Raw Materials & Components	Get a 7-Day Free Trial							-	8.13	-	-	-

HBM Holdings Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

HBM Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (HKSE:02142) » Definitions » Inventories, Raw Materials & Components

Comparable Companies

Traded in Other Exchanges

HBMHF:USA 6XY:Germany

Address

218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

Executives

Wang Jingsong	2101 Beneficial owner
Gic Private Limited	2102 Investment manager
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Owap Investment Pte Ltd	2101 Beneficial owner
Gic Special Investments Private Limited	2102 Investment manager
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
South Dakota Trust Company Llc	2301 Trustee
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Pang Kee Chan Hebert
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you
Morgan Stanley & Co. International Plc	2105 Underwriter
Advantech Capital Holdings Ltd.
Harbourbio Llc	2101 Beneficial owner

HBM Holdings Headlines

No Headlines